AGN Media thread, page-192

Due to drug class of previous analogues showing no impact during stroke it’s very rare an alternate drug in the same class has any kind of impact. That is where the high probability of failure is for AGN. It really just needs to show a 5 percent impact of positivity because nothing is out there approved at the moment. I like NYR because the drug is a small molecule and not a peptide so will have a much stronger response in the body and secondly it’s a new drug class the first of its kind.

But AGN in it for safety and pre clinical announcements coming up as the drug class has already passed this many times before so success is 100 percent with day traders jumping in for the uplift